Annual Current Liabilities
$3.44 M
-$256.80 K-6.95%
31 December 2023
Summary:
Inhibikase Therapeutics annual total current liabilities is currently $3.44 million, with the most recent change of -$256.80 thousand (-6.95%) on 31 December 2023. During the last 3 years, it has fallen by -$1.28 million (-27.18%). IKT annual current liabilities is now -27.18% below its all-time high of $4.72 million, reached on 31 December 2020.IKT Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Current Liabilities
$4.91 M
+$1.20 M+32.47%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly total current liabilities is currently $4.91 million, with the most recent change of +$1.20 million (+32.47%) on 30 September 2024. Over the past year, it has increased by +$2.17 million (+78.99%). IKT quarterly current liabilities is now -17.02% below its all-time high of $5.91 million, reached on 30 September 2020.IKT Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Current Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -7.0% | +79.0% |
| 3 y3 years | -27.2% | +81.2% |
| 5 y5 years | -5.1% | - |
IKT Current Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -27.2% | at low | at high | +84.2% |
| 5 y | 5 years | -27.2% | at low | -17.0% | +156.6% |
| alltime | all time | -27.2% | at low | -17.0% | +156.6% |
Inhibikase Therapeutics Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $4.91 M(+32.5%) |
| June 2024 | - | $3.70 M(-12.5%) |
| Mar 2024 | - | $4.23 M(+23.1%) |
| Dec 2023 | $3.44 M(-6.9%) | $3.44 M(+25.4%) |
| Sept 2023 | - | $2.74 M(+0.3%) |
| June 2023 | - | $2.73 M(+2.6%) |
| Mar 2023 | - | $2.66 M(-27.9%) |
| Dec 2022 | $3.70 M | $3.70 M(+15.0%) |
| Sept 2022 | - | $3.21 M(-28.4%) |
| June 2022 | - | $4.49 M(+2.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $4.38 M(+8.0%) |
| Dec 2021 | $4.05 M(-14.1%) | $4.05 M(+49.7%) |
| Sept 2021 | - | $2.71 M(+41.6%) |
| June 2021 | - | $1.91 M(-46.7%) |
| Mar 2021 | - | $3.59 M(-24.0%) |
| Dec 2020 | $4.72 M(+11.0%) | $4.72 M(-20.2%) |
| Sept 2020 | - | $5.91 M(+29.4%) |
| June 2020 | - | $4.57 M(+3.2%) |
| Mar 2020 | - | $4.43 M(+4.1%) |
| Dec 2019 | $4.25 M(+17.3%) | $4.25 M |
| Dec 2018 | $3.62 M | - |
FAQ
- What is Inhibikase Therapeutics annual total current liabilities?
- What is the all time high annual current liabilities for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual current liabilities year-on-year change?
- What is Inhibikase Therapeutics quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly current liabilities year-on-year change?
What is Inhibikase Therapeutics annual total current liabilities?
The current annual current liabilities of IKT is $3.44 M
What is the all time high annual current liabilities for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual total current liabilities is $4.72 M
What is Inhibikase Therapeutics annual current liabilities year-on-year change?
Over the past year, IKT annual total current liabilities has changed by -$256.80 K (-6.95%)
What is Inhibikase Therapeutics quarterly total current liabilities?
The current quarterly current liabilities of IKT is $4.91 M
What is the all time high quarterly current liabilities for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly total current liabilities is $5.91 M
What is Inhibikase Therapeutics quarterly current liabilities year-on-year change?
Over the past year, IKT quarterly total current liabilities has changed by +$2.17 M (+78.99%)